0001214659-26-004806
SEC filingAlzamend Neuro, Inc. held its 2026 annual stockholder meeting on April 17, electing seven directors and approving auditor ratification, advisory executive compensation, 2025 Stock Incentive Plan, Nasdaq compliance equity issuances, reverse stock split authorization, and meeting adjournments.
Alzamend Neuro's annual meeting saw unanimous approval across all seven proposals, signaling strong shareholder alignment with board recommendations amid 3,804,741 outstanding voting shares. Director elections succeeded with comfortable majorities, ensuring continuity in governance. The ratification of Haskell & White LLP provides accounting stability for the upcoming fiscal year. While advisory say-on-pay passed, the 69% For vote indicates room for compensation scrutiny. The 2025 Stock Incentive Plan's approval, at 65% For, enables equity-based incentives critical for talent retention in biotech. Nasdaq compliance for director/executive equity grants passed, averting potential listing issues. The reverse stock split authorization offers board flexibility to meet exchange requirements through April 2027, a common tool for Nasdaq-listed microcaps facing share price pressures. Adjournment approval ensures procedural robustness. Overall, results reinforce board control and strategic flexibility without dissident activity.